Clonal evolution of glioblastoma under therapy

Nature Genetics

Volumn 48, Issue 7, 2016, Pages 768-776

  Wang, Jiguang ^a   Cazzato, Emanuela ^b   Ladewig, Erik ^a   Frattini, Veronique ^a   Rosenbloom, Daniel I S ^a   Zairis, Sakellarios ^a   Abate, Francesco ^a   Liu, Zhaoqi ^a   Elliott, Oliver ^a   Shin, Yong Jae ^c   Lee, Jin Ku ^c   Lee, In Hee ^c   Park, Woong Yang ^c   Eoli, Marica ^b   Blumberg, Andrew J ^d   Lasorella, Anna ^a   Nam, Do Hyun ^c,e   Finocchiaro, Gaetano ^b   Iavarone, Antonio ^a   Rabadan, Raul ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MISMATCH REPAIR PROTEIN PMS2; PMS1 PROTEIN; PROTEIN MLH1; PROTEIN MLH2; PROTEIN MSH2; PROTEIN MSH4; PROTEIN MSH5; PROTEIN MSH6; SHORT HAIRPIN RNA; TEMOZOLOMIDE; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LTBP4 PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL PROLIFERATION; CLONAL EVOLUTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA BINDING; DNA SEQUENCE; EVOLUTIONARY RATE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENOME ANALYSIS; GENOMICS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; INDEL MUTATION; LTBP4 GENE; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERTANT; RNA SEQUENCE; SILENT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL; TRANSCRIPTOMICS; TUMOR GROWTH; TUMOR RECURRENCE; UPREGULATION; ZYGOSITY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER GRADING; GENE EXPRESSION REGULATION; GENETICS; LONGITUDINAL STUDY; MUTATION; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL PROLIFERATION; CLONAL EVOLUTION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LATENT TGF-BETA BINDING PROTEINS; LONGITUDINAL STUDIES; MUTATION; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 84976318961     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3590     Document Type: Article

References (61)

1. Ricard, D. et al. Primary brain tumours in adults. Lancet 379, 1984-1996 (2012).
2. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
3. Frattini, V. et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141-1149 (2013).
4. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
5. Mazor, T. et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28, 307-317 (2015).
6. Kim, J. et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28, 318-328 (2015).
7. Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25, 316-327 (2015).
8. Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 (1976).
9. Nordling, C. O. A new theory on cancer-inducing mechanism. Br. J. Cancer 7, 68-72 (1953).
10. Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8, 1-12 (1954).
11. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 110, 4009-4014 (2013).
12. Gill, B. J. et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc. Natl. Acad. Sci. USA 111, 12550-12555 (2014).
13. Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014).
14. Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458-468 (2015).
15. Trifonov, V., Pasqualucci, L., Tiacci, E., Falini, B. & Rabadan, R. SAVI: a statistical algorithm for variant frequency identification. BMC Syst. Biol. 7 (suppl. 2), S2 (2013).
16. Melamed, R. D., Wang, J., Iavarone, A. & Rabadan, R. An information theoretic method to identify combinations of genomic alterations that promote glioblastoma J. Mol. Cell Biol. 7, 203-213 (2015).
17. Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22, 398-406 (2012).
18. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
19. Stieglitz, E. et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat. Genet. 47, 1326-1333 (2015).
20. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987-3991 (2006).
21. Yip, S. et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15, 4622-4629 (2009).
22. Cahill, D. P. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038-2045 (2007).
23. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
24. Miyazono, K., Olofsson, A., Colosetti, P. & Heldin, C. H. A role of the latent TGF-1-binding protein in the assembly and secretion of TGF-1. EMBO J. 10, 1091-1101 (1991).
25. Sterner-Kock, A. et al. Disruption of the gene encoding the latent transforming growth factor-binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev. 16, 2264-2273 (2002).
26. Mermel, C. H. et al. GISTIC2. 0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
27. Trifonov, V., Pasqualucci, L., Dalla Favera, R. & Rabadan, R. MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. BMC Syst. Biol. 7, 25 (2013).
28. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235 (2012).
29. Di Stefano, A. L. et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin. Cancer Res. 21, 3307-3317 (2015).
30. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
31. Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 18, 6097-6100 (1990).
32. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
33. Sakellarios Zairis, H. K., Blumberg, A. & Rabadan, R. Moduli spaces of phylogenetic trees describing tumor evolutionary patterns. Lect. Notes Computer Sci. 8609, 528-839 (2014).
34. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
35. Yates, L. R. & Campbell, P. J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795-806 (2012).
36. Wang, J. et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. eLife 3, e02869 (2014).
37. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
38. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
39. Kuan, C. T., Wikstrand, C. J. & Bigner, D. D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8, 83-96 (2001).
40. Torres-García, W. et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30, 2224-2226 (2014).
41. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
42. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
43. Anido, J. et al. TGF-receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655-668 (2010).
44. Han, J., Alvarez-Breckenridge, C. A., Wang, Q. E. & Yu, J. TGF-signaling and its targeting for glioma treatment. Am. J. Cancer Res. 5, 945-955 (2015).
45. Joseph, J. V., Balasubramaniyan, V., Walenkamp, A. & Kruyt, F. A. TGF-as a therapeutic target in high grade gliomas-promises and challenges. Biochem. Pharmacol. 85, 478-485 (2013).
46. Kaminska, B., Kocyk, M. & Kijewska, M. TGF signaling and its role in glioma pathogenesis. Adv. Exp. Med. Biol. 986, 171-187 (2013).
47. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
48. Massagué, J. TGF in cancer. Cell 134, 215-230 (2008).
49. Fakhrai, H. et al. Eradication of established intracranial rat gliomas by transforming growth factor antisense gene therapy. Proc. Natl. Acad. Sci. USA 93, 2909-2914 (1996).
50. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
51. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002).
52. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
53. Khalili, J. S., Hanson, R. W. & Szallasi, Z. In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. OncoImmunology 1, 1281-1289 (2012).
54. Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004).
55. Magi, A. et al. EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol. 14, R120 (2013).
56. Iyer, M. K., Chinnaiyan, A. M. & Maher, C. A. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903-2904 (2011).
57. Abate, F. et al. Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. BMC Syst. Biol. 8, 97 (2014).
58. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
59. Niola, F. et al. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J. Clin. Invest. 123, 405-417 (2013).
60. Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318-325 (2010).
61. Zhao, X. et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat. Cell Biol. 10, 643-653 (2008).